Key result
Elevated preoperative adiponectin linked to ~190% higher 31-365-day mortality risk in non-diabetic cardiac surgery patients.
Why the study?
Does elevated preoperative insulin resistance or adiponectin predict adverse outcomes in non-diabetic patients undergoing elective cardiac surgery?
Cohort (n=836)
No
Does elevated preoperative insulin resistance or adiponectin predict adverse outcomes in non-diabetic patients undergoing elective cardiac surgery?
Odds Ratio: 2.9 (95% CI 1.3–6.4)
Absolute Event Rate: 8.2% vs 2.1%
Elevated preoperative adiponectin levels, but not insulin resistance, are strong predictors of long-term mortality in non-diabetic patients undergoing elective cardiac surgery.
May flag higher long-term mortality risk in non-diabetic cardiac surgery patients; leaves open whether adiponectin refines existing risk models.
BACKGROUND: Insulin resistance and adiponectin are markers of cardio-metabolic disease and associated with adverse cardiovascular outcomes. The present study examined whether preoperative insulin resistance or adiponectin were associated with short- and long-term adverse outcomes in non-diabetic patients undergoing elective cardiac surgery. METHODS: In a prospective study, we assessed insulin resistance and adiponectin levels from preoperative fasting blood samples in 836 patients undergoing cardiac surgery. Population-based medical registries were used for postoperative follow-up. Outcomes included all-cause death, myocardial infarction or percutaneous coronary intervention, stroke, re-exploration, renal failure, and infections. The ability of insulin resistance and adiponectin to predict clinical adverse outcomes was examined using receiver operating characteristics. RESULTS: Neither insulin resistance nor adiponectin were statistically significantly associated with 30-day mortality, but adiponectin was associated with an increased 31-365-day mortality (adjusted odds ratio 2.9 [95% confidence interval 1.3-6.4]) comparing the upper quartile with the three lower quartiles. Insulin resistance was a poor predictor of adverse outcomes. In contrast, the predictive accuracy of adiponectin (area under curve 0.75 [95% confidence interval 0.65-0.85]) was similar to that of the EuroSCORE (area under curve 0.75 [95% confidence interval 0.67-0.83]) and a model including adiponectin and the EuroSCORE had an area under curve of 0.78 [95% confidence interval 0.68-0.88] concerning 31-365-day mortality. CONCLUSIONS: Elevated adiponectin levels, but not insulin resistance, were associated with increased mortality and appear to be a strong predictor of long-term mortality. Additional studies are warranted to further clarify the possible clinical role of adiponectin assessment in cardiac surgery. TRIAL REGISTRATION: The Danish Data Protection Agency; reference no. 2007-41-1514.
No takes yet. Share an insight, caveat, or question.
Mikkelsen et al. (2010) conducted a cohort in Non-diabetic patients undergoing elective cardiac surgery (n=836). Elevated preoperative adiponectin (upper quartile) vs. Lower three quartiles of adiponectin was evaluated on 31-365-day all-cause mortality (adjusted OR 2.9, 95% CI 1.3-6.4). Elevated preoperative adiponectin levels were associated with an increased risk of 31-365-day mortality (adjusted OR 2.9) compared to lower levels in non-diabetic patients undergoing elective cardiac surgery.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: